{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:17:57Z","timestamp":1793881077528,"version":"4.7.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004097","name":"Fondation ARC pour la Recherche sur le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014808","name":"Groupement des Entreprises Fran\u00e7aises dans la lutte contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014808","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008123","name":"Centre Scientifique de Monaco","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008123","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Healthy Longevity"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.lanhl.2025.100812","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T11:58:05Z","timestamp":1771243085000},"page":"100812","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Hypofractionated split-course versus standard radiotherapy in frail older patients with head and neck squamous-cell carcinoma (ELAN-RT trial): a non-inferiority, multicentre, open-label, randomised controlled trial"],"prefix":"10.1016","volume":"7","author":[{"given":"C\u00e9cile","family":"Ortholan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Aup\u00e9rin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yungan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6106-7570","authenticated-orcid":false,"given":"Sophie","family":"Renard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2442-2879","authenticated-orcid":false,"given":"Yoann","family":"Pointreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9drik","family":"Lafond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9266-8638","authenticated-orcid":false,"given":"Guillaume","family":"Bera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Boisselier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Benezery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9711-3807","authenticated-orcid":false,"given":"S\u00e9verine","family":"Racadot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Huguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Bollet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine Laurent","family":"Braccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Jacquot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9460-4995","authenticated-orcid":false,"given":"Julie","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Di Rito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Wiazzane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Goineau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Dupin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lysian","family":"Cartier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Ruffier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadir","family":"Cheurfa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Schwob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Mertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Le Caer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Bourhis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00ebl","family":"Guigay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu-Shan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanhl.2025.100812_bib2","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanhl.2025.100812_bib3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","article-title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients","volume":"92","author":"Pignon","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.lanhl.2025.100812_bib4","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.radonc.2021.01.013","article-title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group","volume":"156","author":"Lacas","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.lanhl.2025.100812_bib5","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0140-6736(06)69121-6","article-title":"Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis","volume":"368","author":"Bourhis","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.lanhl.2025.100812_bib6","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1634\/theoncologist.2012-0427","article-title":"Treatment of older patients with head and neck cancer: a review","volume":"18","author":"VanderWalde","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.lanhl.2025.100812_bib7","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3390\/cancers14030472","article-title":"Head and neck squamous cell carcinoma in elderly patients: role of radiotherapy and chemotherapy","volume":"14","author":"Fasano","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"21","key":"10.1016\/j.lanhl.2025.100812_bib8","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1200\/JCO.2007.14.8841","article-title":"Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis","volume":"26","author":"Machtay","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lanhl.2025.100812_bib9","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.ijrobp.2017.02.022","article-title":"The older adult with locoregionally advanced head and neck squamous cell carcinoma: knowledge gaps and future direction in assessment and treatment","volume":"98","author":"Maggiore","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.lanhl.2025.100812_bib10","first-page":"526","article-title":"Radiation therapy in cancer patients 80 years of age and older","volume":"23","author":"Wasil","year":"2000","journal-title":"Am J Clin Oncol Cancer Clin Trials"},{"key":"10.1016\/j.lanhl.2025.100812_bib11","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1080\/02841860902740899","article-title":"Hypofractionated radiotherapy denoted as the \"Christie scheme\": an effective means of palliating patients with head and neck cancers not suitable for curative treatment","volume":"48","author":"Al-mamgani","year":"2009","journal-title":"Acta Oncol"},{"key":"10.1016\/j.lanhl.2025.100812_bib12","first-page":"933","article-title":"Split-course accelerated hypofractionated radiotherapy (SCAHRT): a safe and effective option for head and neck cancer in the elderly or infirm","volume":"36","author":"Bledsoe","year":"2016","journal-title":"Anticancer Res"},{"key":"10.1016\/j.lanhl.2025.100812_bib13","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.canrad.2020.03.013","article-title":"Split-course hypofractionated radiotherapy for aged and frail patients with head and neck cancers. A retrospective study of 75 cases","volume":"24","author":"Benhmida","year":"2020","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.lanhl.2025.100812_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.761393","article-title":"Hypofractionated radiotherapy in head and neck cancer elderly patients: a feasibility and safety systematic review for the clinician","volume":"11","author":"Piras","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.lanhl.2025.100812_bib15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0167-8140(97)00094-7","article-title":"A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer","volume":"44","author":"Dische","year":"1997","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.lanhl.2025.100812_bib16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0167-8140(97)01904-X","article-title":"Importance of overall treatment time for the outcome of radiotherapy of advanced head and neck carcinoma: dependency on tumor differentiation","volume":"43","author":"Hansen","year":"1997","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.lanhl.2025.100812_bib17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0167-8140(02)00439-5","article-title":"The adverse effect of treatment prolongation in cervical cancer by high-dose-rate intracavitary brachytherapy","volume":"67","author":"Chen","year":"2003","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.lanhl.2025.100812_bib18","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ijrobp.2007.03.010","article-title":"Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumours sites and practical methods for compensation","volume":"68","author":"Bese","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.lanhl.2025.100812_bib19","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/COC.0b013e3181967dd0","volume":"32","author":"McCloskey","year":"2009","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.lanhl.2025.100812_bib20","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jamaoncol.2020.0809","article-title":"Factors associated with chemoradiation therapy interruption and non-completion among patients with squamous cell anal carcinoma","volume":"6","author":"Raphael","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.lanhl.2025.100812_bib21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0360-3016(00)00663-5","article-title":"A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003","volume":"48","author":"Fu","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.lanhl.2025.100812_bib22","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.1016\/S2666-7568(23)00284-2","article-title":"Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial","volume":"5","author":"Guigay","year":"2024","journal-title":"Lancet Healthy Longev"},{"key":"10.1016\/j.lanhl.2025.100812_bib23","doi-asserted-by":"crossref","first-page":"e392","DOI":"10.1016\/S2666-7568(24)00048-5","article-title":"Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, single-arm, phase 2 trial","volume":"5","author":"Guigay","year":"2024","journal-title":"Lancet Healthy Longev"},{"key":"10.1016\/j.lanhl.2025.100812_bib24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.radonc.2006.03.009","article-title":"Proposal for the delineation of the nodal CTV in the node-positive and the post-operative neck","volume":"79","author":"Gr\u00e9goire","year":"2006","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.lanhl.2025.100812_bib25","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.radonc.2003.09.011","article-title":"CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC,RTOG consensus guidelines","volume":"69","author":"Gr\u00e9goire","year":"2003","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.lanhl.2025.100812_bib27","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1002\/cncr.23931","article-title":"Head and neck squamous cell carcinoma in patients aged > or = 80 years: patterns of care and survival","volume":"113","author":"Italiano","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.lanhl.2025.100812_bib28","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/hed.25969","article-title":"Outcomes for elderly patients 75 years and older treated with curative intent radiotherapy for mucosal squamous cell carcinomas of the head and neck","volume":"42","author":"Horsley","year":"2020","journal-title":"Head Neck"},{"key":"10.1016\/j.lanhl.2025.100812_bib29","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13014-020-1481-z","article-title":"Radiotherapy for geriatric head-and-neck cancer patients: what is the value of standard treatment in the elderly?","volume":"15","author":"Haehl","year":"2020","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.lanhl.2025.100812_bib30","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1093\/annonc\/mdx354","article-title":"Changes in the use of end points in clinical trials for elderly cancer patients over time","volume":"28","author":"Le Saux","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lanhl.2025.100812_bib31","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.oraloncology.2016.06.016","article-title":"High-dose hypofractionated radiotherapy is effective and safe for tumors in the head-and-neck","volume":"60","author":"Teckie","year":"2016","journal-title":"Oral Oncol"}],"container-title":["The Lancet Healthy Longevity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266675682500131X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266675682500131X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T15:45:00Z","timestamp":1786031100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266675682500131X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S266675682500131X"],"URL":"https:\/\/doi.org\/10.1016\/j.lanhl.2025.100812","relation":{},"ISSN":["2666-7568"],"issn-type":[{"value":"2666-7568","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypofractionated split-course versus standard radiotherapy in frail older patients with head and neck squamous-cell carcinoma (ELAN-RT trial): a non-inferiority, multicentre, open-label, randomised controlled trial","name":"articletitle","label":"Article Title"},{"value":"The Lancet Healthy Longevity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanhl.2025.100812","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100812"}}